Home › Compare › CFRX vs XYLD

CFRX vs XYLD: Dividend Comparison 2026

CFRX yields 4000.00% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CFRX wins by $7175340620755.84M in total portfolio value
10 years
CFRX
CFRX
● Live price
4000.00%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7175340620755.87M
Annual income
$6,839,006,593,197,835,000.00
Full CFRX calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — CFRX vs XYLD

📍 CFRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCFRXXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CFRX + XYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CFRX pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CFRX
Annual income on $10K today (after 15% tax)
$340,000.00/yr
After 10yr DRIP, annual income (after tax)
$5,813,155,604,218,160,000.00/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, CFRX beats the other by $5,813,155,604,218,157,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CFRX + XYLD for your $10,000?

CFRX: 50%XYLD: 50%
100% XYLD50/50100% CFRX
Portfolio after 10yr
$3587670310377.95M
Annual income
$3,419,503,296,598,919,000.00/yr
Blended yield
95.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CFRX right now

CFRX
Analyst Ratings
1
Strong
1
Buy
3
Hold
Consensus: Hold
Altman Z
-60.9
Piotroski
1/9
XYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CFRX buys
0
XYLD buys
0
No recent congressional trades found for CFRX or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCFRXXYLD
Forward yield4000.00% ✓10.98%
Annual dividend / share$2.00$4.30 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$7175340620755.87M ✓$25.3K
Annual income after 10y$6,839,006,593,197,835,000.00 ✓$3,219.02
Total dividends collected$7152397773804.84M ✓$19.6K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: CFRX vs XYLD ($10,000, DRIP)

YearCFRX PortfolioCFRX Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$410,700$400,000.00$10,818$1,098.39+$399.9K → CFRX
2$15,792,720$15,353,271.03$11,738$1,222.51+$15.78M → CFRX
3$568,657,142$551,758,931.89$12,774$1,364.64+$568.64M → CFRX
4$19,176,207,860$18,567,744,718.20$13,944$1,527.86+$19176.19M → CFRX
5$605,696,028,890$585,177,486,479.73$15,270$1,715.87+$605696.01M → CFRX
6$17,922,210,653,594$17,274,115,902,681.27$16,775$1,933.09+$17922210.64M → CFRX
7$496,869,793,504,300$477,693,028,104,954.00$18,490$2,184.87+$496869793.49M → CFRX
8$12,908,672,105,251,704$12,377,021,426,202,104.00$20,450$2,477.63+$12908672105.23M → CFRX
9$314,330,866,876,668,540$300,518,587,724,049,200.00$22,697$2,819.19+$314330866876.65M → CFRX
10$7,175,340,620,755,871,000$6,839,006,593,197,835,000.00$25,280$3,219.02+$7175340620755.84M → CFRX

CFRX vs XYLD: Complete Analysis 2026

CFRX — Stock

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

Full CFRX Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this CFRX vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CFRX vs SCHDCFRX vs JEPICFRX vs OCFRX vs KOCFRX vs MAINCFRX vs QYLDCFRX vs JEPQCFRX vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.